Dr Craig Jamieson


Pure and Applied Chemistry


Recent advances in the generation of nitrilium betaine 1,3-dipoles
Livingstone Keith, Little Gemma, Jamieson Craig
Synthesis (2021)
Ruthenium-catalyzed ester reductions applied to pharmaceutical intermediates
Shaalan Youssef, Boulton Lee, Jamieson Craig
Organic Process Research and Development Vol 24, pp. 2745-2751 (2020)
UV-induced 1,3,4-oxadiazole formation from 5-substituted tetrazoles and carboxylic acids in flow
Green Luke, Livingstone Keith, Bertrand Sophie, Peace Simon, Jamieson Craig
Chemistry - A European Journal Vol 26, pp. 14866-14870 (2020)
Transition metal-free coupling of 1,3-dipoles and boronic acids as a sustainable approach to C-C bond formation
Livingstone Keith, Bertrand Sophie, Kennedy Alan R, Jamieson Craig
Chemistry - A European Journal Vol 26, pp. 10591-10597 (2020)
Design and development of a macrocyclic series targeting phosphoinositide 3-kinase δ
Spencer Jonathan A, Baldwin Ian R, Barton Nick, Chung Chun-Wa, Convery Máire A, Edwards Christopher D, Jamieson Craig, Mallett David N, Rowedder James E, Rowland Paul, Thomas Daniel A, Hardy Charlotte J
ACS Medicinal Chemistry Letters Vol 11, pp. 1386-1391 (2020)
A one-pot Suzuki-hydrogenolysis protocol for the modular synthesis of 2,5-diaryltetrazoles
Livingstone Keith, Bertrand Sophie, Jamieson Craig
Journal of Organic Chemistry Vol 85, pp. 7413-7423 (2020)

More publications

Research interests


Craig Jamieson earned his BSc (Hons) in Chemistry at the University of Glasgow in 1996. His PhD studies were carried out under the direction of Professor R Ramage at the University of Edinburgh (1999).  Following postdoctoral research under the supervision of Professor S V Ley at the University of Cambridge, in 2001 he was appointed as a Principal Scientist in GlaxoSmithKline's Discovery Medicinal Chemistry group working on a range of exploratory medicinal chemistry programmes.  In 2004, Dr Jamieson joined Organon Laboratories (later Merck Research Labs) as a Group Leader in the Medicinal Chemistry Department, with responsibility for hit to clincal candidate optimisation.  In August 2010 he was appointed as a John Anderson Research Lecturer in Chemical Biology, based in the Department of Pure and Applied Chemistry at the University of Strathclyde.

Research Interests

A major area of focus for our research continues to be in the Chemistry-Biology-Medicine continuum.  In this regard, we have a number of active programmes centred around hit and lead identification on disease targets and mechanisms in areas of significant societal need, particularly in diseases of ageing.  Allied to our work in the medicinal chemistry sphere, we also have a keen interest in the development of novel, enabling synthetic methodologies to enhance the armamentarium of molecule makers working in our arena.  We collaborate with groups and industrial partners locally, nationally and globally in order to effectively meet our research goals.

Professional activities

Gyros Protein Technologies
Visiting researcher
Almac Sciences
Visiting researcher
Aldeyra Therapeutics Inc
Arc Scientific
Syngenta Limited
Visiting researcher
Journal of the American Chemical Society (Journal)
Peer reviewer

More professional activities


Identifying New Drugs for the Treatment of Castrate Resistant Prostate Cancer
Jamieson, Craig (Principal Investigator)
01-Jan-2020 - 31-Jan-2022
Industrial Case Account - University of Strathclyde 2020 | Linden, Otto
Burley, Glenn (Principal Investigator) Jamieson, Craig (Co-investigator) Linden, Otto (Research Co-investigator)
01-Jan-2020 - 01-Jan-2024
Industrial Case Account - University of Strathclyde 2020 | Gibson, Mhairi
Jamieson, Craig (Principal Investigator) Burley, Glenn (Co-investigator) Gibson, Mhairi (Research Co-investigator)
01-Jan-2020 - 01-Jan-2024
Development and preclinical validation of novel PAR2 inhibitors for the treatment of Osteoarthritis
McIntosh, Kathryn (Principal Investigator) Crilly, Anne (Co-investigator) Jamieson, Craig (Co-investigator) Plevin, Robin (Co-investigator) Rattray, Zahra (Co-investigator)
01-Jan-2020 - 30-Jan-2022
The Androgen Receptor-amino terminal domain a Novel Druggable Target in the Treatment of Castrate
Jamieson, Craig (Principal Investigator)
01-Jan-2019 - 31-Jan-2022
Doctoral Training Partnership 2018-19 University of Strathclyde | Mowat, Jenna
Jamieson, Craig (Principal Investigator) Burley, Glenn (Co-investigator) Mowat, Jenna (Research Co-investigator)
01-Jan-2019 - 01-Jan-2023

More projects


Pure and Applied Chemistry
Thomas Graham Building

Location Map

View University of Strathclyde in a larger map